Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 1

Interventions

Methotrexate 3olokizumab 2veltuzumab 1upadacitinib 1tocilizumab 1mavrilimumab 1golimumab 1andecaliximab 1Vaccines 1Tumor Necrosis Factor Inhibitors 1TACI receptor-IgG Fc fragment fusion protein 1Saline Solution 1RC-18 1Interleukin 1 Receptor Antagonist Protein 1ISIS104838 1Herpes Zoster Vaccine 1Bortezomib 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Arthritis, Rheumatoid × ISIS104838 × Clear all
NCT00048321 2022-12-05

ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

Ionis Pharmaceuticals, Inc.

Phase 2 Completed
160 enrolled

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡